Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate ...

The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...

Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US Food and Drug Administration, offering patients greater choice as the ...

FDA approves Sanofi's RNAi hemophilia drug fitusiran, licensed from Alnylam, to treat both hemophilia A and B by lowering ...

Bispecific antibodies first reached patients as cancer treatments, but a growing number of companies are working to expand these therapies to autoimmune diseases. Sanofi is adding a new contender ...

This drug is currently a key top-line driver for both SNY and REGN. In 2024, Sanofi recorded more than €13 billion from Dupixent product sales, indicating 23% year-over-year growth. The reported ...

A similar regulatory filing for the drug is currently under review by the EMA, which is also supported by data from these studies. Per Sanofi, the above results make tolebrutinib the first and the ...

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...